Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Recent advances in the diagnosis and management of childhood acute promyelocytic leukemia

  • Yoo, Eun-Sun (Division of Pediatric Hematology-Oncology, Department of Pediatrics, Ewha Womans University, School of Medicine)
  • Received : 2011.02.18
  • Accepted : 2011.03.07
  • Published : 2011.03.15
Download PDF
⟨ Previous Next ⟩

Abstract

Since the successful introduction of all-trans-retinoic acid (ATRA) and its combination with anthracycline-containing chemotherapy, the prognosis for acute promyelocytic leukemia (APL) has markedly improved. With ATRA and anthracycline-based-chemotherapy, the complete remission rate is greater than 90%, and the long-term survival rate is 70-89%. Moreover, arsenic trioxide (ATO), which was introduced for APL treatment in 1994, resulted in excellent remission rates in relapsed patients with APL, and more recently, several clinical studies have been designed to explore its role in initial therapy either alone or in combination with ATRA. APL is a rare disease in children and is frequently associated with hyperleukocytosis, which is a marker for higher risk of relapse and an increased incidence of microgranular morphology. The frequency of occurrence of the promyelocytic leu-kemia/retinoic acid receptor-alpha (PML/$RAR{\alpha}$) isoforms bcr 2 and bcr 3 is higher in children than in adults. Although recent clinical studies have reported comparable long-term survival rates in patients with APL, therapy for APL in children is challenging because of the risk of early death and the potential long-term cardiac toxicity resulting from the need to use high doses of anthracyclines. Additional prospective, randomized, large clinical trials are needed to address several issues in pediatric APL and to possibly minimize or eliminate the need for chemotherapy by combining ATRA and ATO. In this review article, we discuss the molecular pathogenesis, diagnostic progress, and most recent therapeutic advances in the treatment of children with APL.

Keywords

References

  1. Schwartz EL, Sartorelli AC. Structure-activity relationships for the induction of differentiation of HL-60 human acute promyelocytic leukemia cells by anthracyclines. Cancer Res 1982;42:2651-2655.
  2. Grignani F, Ferrucci PF, Testa U, Talamo G, Fagioli M, Alcalay M, et al. The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 1993;74:423-431. https://doi.org/10.1016/0092-8674(93)80044-F
  3. Mann G, Reinhardt D, Ritter J, Hermann J, Schmitt K, Gadner H, et al. Treatment with all-trans retinoic acid in acute promyelocytic leukemia reduces early deaths in children. Ann Hematol 2001;80:417-422. https://doi.org/10.1007/s002770100304
  4. de Botton S, Coiteux V, Chevret S, Rayon C, Vilmer E, Sanz M, et al. Outcome of childhood acute promyelocytic leukemia with all-transretinoic acid and chemotherapy. J Clin Oncol 2004;22:1404-1412. https://doi.org/10.1200/JCO.2004.09.008
  5. Testi AM, Biondi A, Lo Coco F, Moleti ML, Giona F, Vignetti M, et al. GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood 2005;106:447-453. https://doi.org/10.1182/blood-2004-05-1971
  6. Ortega JJ, Madero L, Martin G, Verdeguer A, Garcia P, Parody P, et al. Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group. J Clin Oncol 2005;23:7632-7640. https://doi.org/10.1200/JCO.2005.01.3359
  7. Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, et al. Preliminary results from the North American acute promyelocytic leukemia (APL) study C9710 (abstract). Blood 2006;108:566. https://doi.org/10.1182/blood-2005-12-4777
  8. Luo XQ, Ke ZY, Huang LB, Guan XQ, Zhang YC, Zhang XL. Improved outcome for Chinese children with acute promyelocytic leukemia: a comparison of two protocols. Pediatr Blood Cancer 2009;53:325-8. https://doi.org/10.1002/pbc.22042
  9. Gregory J, Kim H, Alonzo T, Gerbing R, Woods W, Weinstein H, et al. Treatment of children with acute promyelocytic leukemia: results of the first North American Intergroup trial INT0129. Pediatr Blood Cancer 2009;53:1005-10. https://doi.org/10.1002/pbc.22165
  10. Jeddi R, Ghedira H, Ben Abdennebi Y, Kacem K, Ben Amor R, Aissaoui L, et al. ATRA and anthracycline-based chemotherapy in the treatment of childhood acute promyelocytic leukemia (APL): A 10-year experience in Tunisia. Med Oncol 2010;10.
  11. Creutzig U, Zimmermann M, Dworzak M, Urban C, Henze G, Kremens B, et al. Favorable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses. Br J Haematol 2010;149:399-409. https://doi.org/10.1111/j.1365-2141.2010.08107.x
  12. Imaizumi M, Tawa A, Hanada R, Tsuchida M, Tabuchi K, Kigasawa H, et al. Prospective study of a therapeutic regimen with all-trans retinoic acid and anthracyclines in combination of cytarabine in children with acute promyelocytic leukaemia: the Japanese childhood acute myeloid leukaemia cooperative study. Br J Haematol 2011;152:89-98. https://doi.org/10.1111/j.1365-2141.2010.08332.x
  13. Kim MH, Choi CS, Lee JW, Jang PS, Chung NG, Cho B, et al. Outcome of childhood acute promyelocytic leukemia treated using a modified AIDA protocol. Korean J Hematol 2010;45:236-41. https://doi.org/10.5045/kjh.2010.45.4.236
  14. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001;19:3852-60.
  15. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999;94:3315-24.
  16. Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci 2004;101:5328-35. https://doi.org/10.1073/pnas.0400053101
  17. Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: Durable remissions with minimal toxicity. Blood 2006;107:2627-32. https://doi.org/10.1182/blood-2005-08-3532
  18. Mathews V, George B, Chendamarai E, Lakshmi KM, Desire S, Balasubramanian P, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol 2010;28:3866-71. https://doi.org/10.1200/JCO.2010.28.5031
  19. George B, Mathews V, Poonkuzhali B, Shaji RV, Srivastava A, Chandy M. Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experience. Leukemia 2004;18:1587-90. https://doi.org/10.1038/sj.leu.2403480
  20. Wang H, Hao L, Wang X, Li J, Wu Q, Bian S. Retrospective study of arsenic trioxide for childhood acute promyelocytic leukemia in China: a single-center experience. Int J Hematol 2010;91:820-5. https://doi.org/10.1007/s12185-010-0575-z
  21. Zhou J, Zhang Y, Li J, Li X, Hou J, Zhao Y, et al. Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia. Blood 2010;115:1697-702. https://doi.org/10.1182/blood-2009-07-230805
  22. Cantu-Rajnoldi A, Biondi A, Jankovic M, Masera G, Rovelli A, Uderzo C, et al. Diagnosis and incidence of acute promyelocytic leukemia (FAB M3 and M3 variant) in childhood. Blood 1993;81:2209-10.
  23. Maule MM, Dama E, Mosso ML, Magnani C, Pastore G, Merletti F. High incidence of acute promyelocytic leukemia in children in northwest Italy, 1980-2003: a report from the Childhood Cancer Registry of Piedmont. Leukemia 2008;22:439-41. https://doi.org/10.1038/sj.leu.2404916
  24. Sanz MA, Vellenga E, Rayon C, Diaz-Mediavilla J, Rivas C, Amutio E, et al. All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood 2004;104:3490-3. https://doi.org/10.1182/blood-2004-04-1642
  25. Kane JR, Head DR, Balazs L, Hulshof MG, Motroni TA, Raimondi SC, et al. Molecular analysis of the PML/RAR alpha chimeric gene in pediatric acute promyelocytic leukemia. Leukemia 1996;10:1296-302.
  26. Sanz MA, Lo Coco F, Martin G, Avvisati G, Rayon C, Barbui T, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000;96:1247-53.
  27. Barbui, T, Finazzi, G, Falenga A. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood 1998;91:3093-102.
  28. Menell JS, Cesarman GM, Jacovina AT, McLaughlin MA, Lev EA, Hajjar KA. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999;340:994-1004. https://doi.org/10.1056/NEJM199904013401303
  29. de The H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanism of cure. Nat Rev Cancer 2010;10:775-83. https://doi.org/10.1038/nrc2943
  30. Vahdat L, Maslak P, Miller WH Jr, Eardley A, Heller G, Scheinberg DA, et al. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 1994;84:3843-9.
  31. Sainty D, Liso V, Cantu-Rajnoldi A, Head D, Mozziconacci MJ, Arnoulet C, et al. A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements. Blood 2000;96:1287-96.
  32. Neame PB, Soamboonsrup P, Leber B, Carter RF, Sunisloe L, Patterson W, et al. Morphology of acute promyelocytic leukemia with cytogenetic or molecular evidence for the diagnosis: characterization of additional microgranular variants. Am J Hematol 1997;56:131-42. https://doi.org/10.1002/(SICI)1096-8652(199711)56:3<131::AID-AJH1>3.0.CO;2-Z
  33. Guglielmi C, Martelli MP, Diverio D, Fenu S, Vegna ML, Cantu- Rajnoldi A, et al. Immunophenotype of adult and childhood acute promyelocytic leukaemia: correlation with morphology, type of PML gene breakpoint and clinical outcome: a cooperative Italian study on 196 cases. Br J Haematol 1998;102:1035-41. https://doi.org/10.1046/j.1365-2141.1998.00871.x
  34. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, et al. Use of alltrans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72:567-72.
  35. Zubizarreta PA, Rose AB, Felice MS, Alfaro E, Delfino S, Cygler AM, et al. Childhood acute promyelocytic leukemia: no benefit of alltransretinoic acid administered in a short-course schedule. Pediatr Hematol Oncol 2000;17:155-62. https://doi.org/10.1080/088800100276514
  36. Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999;94:1192-200.
  37. Ades L, Chevret S, Raffoux E, de Botton S, Guerci A, Pigneux A, et al. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol 2006;24:5703-10. https://doi.org/10.1200/JCO.2006.08.1596
  38. Ades L, Sanz MA, Chevret S, Montesinos P, Chevallier P, Raffoux E, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): A comparison of French-Belgian-Swiss and PETHEMA results. Blood 2008;111:1078-84.
  39. Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 2009;113:1875-91. https://doi.org/10.1182/blood-2008-04-150250
  40. Sanz MA, Montesinos P, Vellenga E, Rayon C, de la Serna J, Parody R, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: Long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. Blood 2008;112:3130-4. https://doi.org/10.1182/blood-2008-05-159632
  41. Lo-Coco F, Avvisati G, Vignetti M, Breccia M, Gallo E, Rambaldi A, et al. Frontline treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: Results of the AIDA-2000 trial of the GIMEMA group. Blood 2010;116:3171-9. https://doi.org/10.1182/blood-2010-03-276196
  42. Sanz MA, Montesinos P, Rayon C, Holowiecka A, de la Serna J, Milone G, et al. PETHEMA and HOVON Groups. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood 2010;115:5137-46. https://doi.org/10.1182/blood-2010-01-266007
  43. Powell BL, Moser B, Stock W, et al. Effect of consolidation with arsenic trioxide (As2O3) on event free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710. ASCO Meeting Abstracts Part I [abstract]. J Clin Oncol 2007;25:2.
  44. Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002;99:759-67. https://doi.org/10.1182/blood.V99.3.759
  45. Asou N, Kishimoto Y, Kiyoi H, Okada M, Kawai Y, Tsuzuki M, et al. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood 2007;110:59-66. https://doi.org/10.1182/blood-2006-08-043992
  46. de Botton S, Chevret S, Coiteux V, Dombret H, Sanz M, San Miguel J, et al. Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial. Leukemia 2003;17:339-42. https://doi.org/10.1038/sj.leu.2402807
  47. Arrigoni P, Beretta C, Silvestri D, Rossi V, Rizzari C, Valsecchi MG, et al. FLT3 internal tandem duplication in childhood acute myeloid leukaemia: association with hyperleucocytosis in acute promyelocytic leukaemia. Br J Haematol 2003;120:89-92. https://doi.org/10.1046/j.1365-2141.2003.04032.x

Cited by

  1. All-transretinoic acid in the treatment of pediatric acute promyelocytic leukemia vol.12, pp.9, 2011, https://doi.org/10.1586/era.12.101
  2. Infections in pediatric acute promyelocytic leukemia: from the canadian infections in acute myeloid leukemia research group vol.13, pp.None, 2011, https://doi.org/10.1186/1471-2407-13-276
  3. Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research Directions : A Scient vol.128, pp.17, 2013, https://doi.org/10.1161/cir.0b013e3182a88099
  4. Treatment of an Acute Promyelocytic Leukemia Relapse Using Arsenic Trioxide and All-Trans-Retinoic in a 6-Year-Old Child vol.31, pp.2, 2014, https://doi.org/10.3109/08880018.2013.876470
  5. A Selenium-Modified Ginseng Polysaccharide Promotes the Apoptosis in Human Promyelocytic Leukemia (HL-60) Cells via a Mitochondrial-Mediated Pathway vol.177, pp.1, 2017, https://doi.org/10.1007/s12011-016-0879-9
  6. Recent advances in acute promyelocytic leukaemia vol.6, pp.None, 2017, https://doi.org/10.12688/f1000research.10736.1
  7. High Expression of RAR β Is a Favorable Factor in Colorectal Cancer vol.2019, pp.None, 2011, https://doi.org/10.1155/2019/7138754